Abstract：
Toxoplasmosis is one of the most dangerous zoonotic diseases, causing serious economic losses worldwide due to abortion and reproductive problems. Vaccination is the best way to prevent disease; thus, it is imperative to develop a candidate vaccine for toxoplasmosis. BAG1 and ROP8 have the potential to become vaccine candidates. In this study, rTgBAG1, rTgROP8, and rTgBAG1-rTgROP8 were used to evaluate the immune effect of vaccines in each group by detecting the humoral and cellular immune response levels of BABL/c mice after immunization and the ability to resist acute and chronic infection with Toxoplasma gondii (T. gondii). We divided the mice into vaccine groups with different proteins, and the mice were immunized on days 0, 14, and 28. The protective effects of different proteins against T. gondii were analysed by measuring the cytokines, serum antibodies, splenocyte proliferation assay results, survival time, and number and diameter of brain cysts of mice after infection. The vaccine groups exhibited substantially higher IgG, IgG1, and IgG2a levels and effectively stimulated lymphocyte proliferation. The levels of IFN-γ and IL-2 in the vaccine group were significantly increased. The survival time of the mice in each vaccine group was prolonged and the diameter of the cysts in the vaccine group was smaller; rTgBAG1-rTgROP8 had a better protection. Our study showed that the rTgBAG1, rTgROP8, and rTgBAG1-rTgROP8 recombinant protein vaccines are partial but effective approaches against acute or chronic T. gondii infection. They are potential candidates for a toxoplasmosis vaccine.
摘要：
弓形虫病是最危险的人畜共患疾病之一,由于堕胎和生殖问题，在全世界造成严重的经济损失。接种疫苗是预防疾病的最佳方法；因此，开发弓形虫病的候选疫苗势在必行。BAG1和ROP8有可能成为候选疫苗。在这项研究中,rTgBAG1，rTgROP8和rTgBAG1-rTgROP8用于通过检测免疫后BABL/c小鼠的体液和细胞免疫应答水平以及抵抗弓形虫急性和慢性感染的能力来评估各组疫苗的免疫效果（T。gondii）。我们将小鼠分成不同蛋白质的疫苗组，并在第0、14和28天免疫小鼠。通过检测细胞因子,分析不同蛋白对弓形虫的保护作用,血清抗体，脾细胞增殖测定结果，生存时间,感染后小鼠脑囊肿的数量和直径。疫苗组表现出更高的IgG，IgG1和IgG2a水平并有效刺激淋巴细胞增殖。疫苗组IFN-γ和IL-2水平显著升高。各疫苗组小鼠存活时间延长,囊肿直径较小;rTgBAG1-rTgROP8具有较好的保护作用。我们的研究表明，rTgBAG1，rTgROP8和rTgBAG1-rTgROP8重组蛋白疫苗是针对急性或慢性弓形虫感染的部分但有效的方法。它们是弓形虫病疫苗的潜在候选者。
